NEW YORK, Sept. 30, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM).Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/dexcom-inc-loss-submission-form/?id=105579&from=4 CLASS PERIOD: January 8, 2024 to July 25, ...

RADNOR, Pa., Sept. 29, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed against DexCom, Inc. ("DexCom") (NASDAQ: DXCM) on behalf of investors who purchased or otherwise acquired DexCom securities between January 8, 2024 to July 25, 2024, inclusive (the "Class Period")  The lead plaintiff deadline is October 21, 2024.CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:If you suffered DexCom losses, you may C ...

NEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) an ...

SAN FRANCISCO, Sept. 27, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM), alleging that the medical device company made misleading statements about its financial performance and growth prospects. Hagens Berman urges DexCom investors who suffered substantial losses to submit your losses now. Class Period: Jan. 8, 2024 – July 25, 2024Lead Plaintiff Deadline: Oct. 21, 2024Visit: www.hbsslaw.com/investor-fraud/DXCMContact the Firm Now: DXCM@hbsslaw.com 844-916- ...

NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) an ...

RADNOR, Pa., Sept. 26, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California against DexCom, Inc. (“DexCom”) (NASDAQ: DXCM) on behalf of investors who purchased or otherwise acquired DexCom securities between January 8, 2024 to July 25, 2024, inclusive (the “Class Period”) The lead plaintiff deadline is October 21, 2024. CONT ...

NEW YORK, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Southern District of California on behalf of those who acquired Dexcom Inc. (“Dexcom” or the “Company”) (NASDAQ: DXCM) securities during the period of January 8, 2024 to July 25, 2024, inclusive (“the Class Period”). Investors have until October 21, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit. [Click h ...

SAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired DexCom Inc. (NASDAQ: DXCM) securities between January 8, 2024 and July 25, 2024. DexCom is an international company that develops, manufactures, and distributes continuous glucose monitoring systems for diabetes management. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In DexCom To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in DexCom between January 8, 2024 to July 25, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Sept. 25, 2024 (GLOBE NEW ...

Two key uncertainties make the prospect of buying it today riskier than is desirable.DexCom (DXCM -0.95%) is not a stock that investors should be rushing to sell. It has a few different opportunities to continue pursuing to generate growth, it has plenty of recurring revenue, and the valuation of its shares is reasonable. But you still shouldn't buy it right now.The odds are good that it'll continue to be a decent performer moving forward. Still, it's facing two key issues that need to be navigated successf ...